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Six cases are described where the medical management of a person’s epilepsy was brought under legal scrutiny. Lessons learnt
from this educational exercise include improving doctor patient communication, the function of a Coroner’s Court, when is
misdiagnosis negligent, the vagaries of expert witnesses, should failure to diagnose a tumour be blamed on the physician or the
service when facilities are inadequate, is failure to recognise a rare drug interaction, failure to warn against an interaction, or
failure to take a proper history, negligent? The conference also examined the legal ramifications of the nurse/doctor relation-
ship in epilepsy care, the place of epilepsy guidelines and, due to its interactive nature, reflected on the audience’s epilepsy
knowledge, which, in places seemed significantly deficient. It was a gripping educational exercise.
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INTRODUCTION
The other day, in clinic, I realized I had made a mis-
take. I had been asked to review a man last seen by
me 2 years before. At that time he had presented for
a second opinion about diagnosis. He had a long his-
tory of recurrent affective disorder—often with fairly
rapid onset and offset—almost invariably of a depres-
sive nature (he had been ‘high’ occasionally). His
astute General Practitioner (GP) wondered whether
these short lived but intense, depressive spells might
have an epileptic basis to them, particularly because
they were often accompanied by an olfactory experi-
ence. He was already taking carbamazepine as a mood
stabilizing drug.
Now, ictal depression does occur and indeed I have
described it1: but in over 30 years practice of epilepsy
I have seen perhaps only half a dozen cases. In all of
them the drop into depression was extremely rapid, the
depressive experience most closely resembled a de-
pressive stupor and recovery was swift, after no more
than an hour or so (although one patient managed to
cut his throat in that hour)1.
There was no doubt that the man in front of me did
have recurrent episodes of depression of psychotic in-
tensity: but they were often of 24 hours duration or
longer and of relatively slow onset and offset: many
seem related to his unhappy life experiences. His ol-
factory experiences seemed affect laden and mood
congruent and were, I thought, as many ‘temporal
lobe symptoms’ are2, related to his psychiatric dis-
order although a little sharper and clearer than usual
in such cases. His electroencephalogram was reported
as showing mild intermittent non-diagnostic slowing
over the left temporal area (a not uncommon finding
in people with affective symptoms) and a high quality
MRI was reported as normal.
On taking what I thought was a thorough history,
I did not get the flavour of temporal lobe epilepsy
and said so—the man departed much relieved that he
had not acquired a diagnosis which would have made
further changes in his life.
Two years later he was back in front of me. All had
gone well (or at least as badly as usual) until 3 months
before this present interview when carbamazepine
had been withdrawn and lithium substituted—fairly
abruptly. Shortly thereafter he had two witnessed
tonic–clonic seizures both preceded by his olfactory
experience. He was admitted to hospital and put on to
1000 mgs a day of sodium valproate. Since then he had
had no further seizures and no further olfactory expe-
riences or depressive episodes. An electroencephalo-
gram now showed significant focal slowing over his
left temporal lobe and an MRI scan (performed on
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the same machine and with the same reporter) now
showed clear evidence of left hippocampal atrophy.
Probably, therefore, the experiences that I had cate-
gorized 2 years before as non-epileptic were actually
epileptic in nature.
I do not think I had been swayed too much by my
usual desire not to make a diagnosis of epilepsy un-
less clinically sure (and by my awareness of the over-
diagnosis of temporal lobe epilepsy by my psychiatric
colleagues in patients with ‘soft’ neurological symp-
toms). My clinical experience and reading of the liter-
ature, however, had been misleading: and this present
patient’s experiences must be added to and modify the
clinical data base stored in my cortex. A salutary ex-
perience!
But one, I reflected, that might have been even more
salutary. Suppose the man had died in his seizure or,
whilst driving, had killed others? What would my po-
sition have been then? In a court of law, could col-
leagues have been found to defend my actions: or
would one have been found to label my diagnosis as
negligent? A missed diagnosis is not necessarily mal-
practice but leaves the perpetrator feeling uneasy.
There were, of course, other explanations for
my patient’s seizures—sudden withdrawal of carba-
mazepine, institution of lithium in someone prone to
seizures: even the loss of his affective symptoms might
be ascribed either to the tonic–clonic seizures them-
selves or to the mood stabilizing effects of valproate.
It would have been an interesting few days in court,
with themes expounded and dismissed (plus, no doubt,
a scornful neurologist or two pontificating on the dan-
gers of letting psychiatrists loose in the world of the
brain). Interesting for the spectators, but stressful for
the defendant. No one likes to have their actions and
decisions tested in a court of law, no matter how well
intentioned they seemed to be at the time.
I reflected on this experience as I began to write
up the results of an interesting educational experiment
the British Branch of the International League Against
Epilepsy had carried out in Edinburgh a few months
previously when we had examined some epilepsy re-
lated cases, that had either come to legal notice or had
come before the courts, to try to learn from them.
Years ago, when I started my medical training, the
management of epilepsy was cheap, non-contentious
and easy. The diagnosis was made on clinical grounds
through experience. Investigation was a skull X-ray
and an EEG (or not): patients were then given either
phenobarbitone or phenytoin (or both) and sent back
to their GP. Some got better, some did not. Some died,
some became wheelchair bound through ataxia, some
became brittle boned, a few went mad, some had de-
formed offspring. That was the way things were with
epilepsy. No one was to blame: it was fate. No need to
blame the doctor, no need to sue: he had done his best.
Now epilepsy management is expensive. Investiga-
tion is complex and often not available or has a long
waiting list although the diagnosis is still a clinical
one. Treatment has advanced and there is a bewilder-
ing variety of drugs to choose from, some much more
costly than others and all claiming to have specific ad-
vantages (but in a Health Service run by managers who
‘know the price of everything but the value of nothing’
cost has more clout than efficacy). Patients may remain
in the hospital clinic now, rather than going back to
their GP, and much of their management may be in the
hands of a specialist nurse. There is much therapeutic
optimism, but patients still fail to get better, may still
die, still suffer side effects (often now because of in-
teractions between medicines), may still go mad and
may still have damaged children.
What has changed is patient and public attitudes to
medical care and responsibility. If someone does not
get better, suffers a medical mishap, or dies then some-
one must be held to account or sued for damages. This
change in attitude had taken doctors by surprise and
unprepared and muttering darkly about lawyers foster-
ing a blame culture for their own ends and politicians
stirring up anti doctor feelings to try to wrest control
from the profession and to conceal the huge gaps in
health care provision that have become the norm in
our third world Health Service. This change has ef-
fected epilepsy management and an increasing number
of epilepsy cases are going through the courts and an
increasing number of clinicians are receiving solicitors
letters alleging that poor or sub-standard seizure man-
agement had led to some mishap to their client and are
seeking compensation. The situation has been compli-
cated by the publication of guidelines for several as-
pects of epilepsy care with the implication that there is
now a standard practice, deviation from which may be
held to be incompetent.
All clinicians who manage epilepsy need to think
about their standard of clinical practice and whether it
would be harshly judged in a court of law or would
be defensible if challenged. They need to think, too,
about the actions of their team and where responsi-
bility lies in the interaction between GP and consul-
tant and, if lack of resources prevents them from fol-
lowing accepted standards of good practice, whether
management rather than the clinician should be held
to account. All of us involved in epilepsy care need to
think about these issues because we are all potentially
at risk, particularly because the United States ‘no win
no fee’ system is developing here and litigants may be
more prepared to ‘try it on’.
The purpose of the symposium held during the An-
nual Scientific Meeting of the British Branch of the
International League Against Epilepsy in Edinburgh in
April 2000 was to examine some of the present stan-
dards of epilepsy management as reflected in the po-
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tential outcome of litigation and in published guide-
lines. Participants in the meeting were given a series of
epilepsy case histories to read before the meeting (and
to bring with them). All these cases had been the sub-
ject of actual or threatened litigation and participants
were asked to put themselves in the position of having
just been in receipt of a solicitor’s letter alleging neg-
ligence. The cases were discussed by a panel of clin-
icians (consultants, GPs and nurses) and a barrister.
Since it is an urban medical myth that what happens in
the US today will happen in the UK next week, there
was also an American clinician as a discussant. There
was an interactive voting system present in order that
audience opinion and knowledge could be tested.
It should be remembered, in assessing the results
of the interactive voting, that the audience (over 400)
contained specialists in epilepsy care, neurologists,
general physicians, GPs, nurse specialists and some
medical students from whom different standards of
knowledge might have been expected.
Note that in the following the case details have been
altered in such a way as to preserve the anonymity of
the patients without effecting the truth of the history.
CASE ONE. SUDDEN DEATH IN EPILEPSY
(SUDEP)
Case history
Jane Hanna (Director of Epilepsy Bereaved) presented
the first case history. A young man with a previ-
ous diagnosis of ‘pseudoseizures’ (jerking down the
right side when walking) was referred to an epilepsy
consultant. The patient had mild right-side weak-
ness following a cerebral birth injury. Investigation
showed that his right-sided seizures were actually
movement-induced tonic–clonic seizures and that he
was also experiencing secondarily generalized tonic–
clonic seizures in his sleep. The seizures were unre-
sponsive to conventional medication but the patient
rejected trying new treatment (this decision was not
recorded in the notes). A year later the patient died
in his sleep of presumed sudden death in epilepsy
(SUDEP). The consultant was invited to attend the in-
quest as a witness to fact.
Further developments
At the inquest, where the consultant was not legally
represented, the patient’s parents appeared (whom the
consultant had never met). They were legally repre-
sented, and during an angry exchange announced that
they would sue the consultant for not telling them that
their son could die of his seizures. They alleged that
an epilepsy advice organization had told them that par-
ents should always be told of the risk of SUDEP. The
following day a local newspaper, naming the consul-
tant, ran the headline ‘Doctor rapped for not warning
of death risk’. The consultant chose not to respond to
the newspaper headline and has heard no more from
the parents.
The audience were asked the questions given in
Table 1 at this point and their responses were recorded.
Discussion
Jane Hanna opined that when considering whether
patients should be warned about SUDEP, an initial
point to be raised is whether physicians should be do-
ing this, bearing in mind that many are not well in-
formed about the disorder. The starting point is there-
fore to ensure that health professionals themselves
are fully informed. Secondly, we should think about
this issue in terms of the ability of patients to par-
ticipate in decisions that may have a direct impact
on their lives. Certainly, in other countries (including
Canada and Australia) the law has developed with re-
gard to information disclosure and states that the ulti-
mate choice of decision making should be for the pa-
tient. Patients need to have information that can help
them achieve a balanced view. It might also be argued
that if the family/carer have information about the fa-
tality risks of seizures, they could employ appropri-
ate first aid/resuscitation procedures. Although we do
not have evidence suggesting that such procedures pre-
vent SUDEP, it may be important that people do not
feel an opportunity to try has been lost. (Some doc-
tors, however, feel that to warn about the (compara-
tively low) risk of SUDEP will increase overprotec-
tion). Initially, when asked, the majority of the audi-
ence felt that all patients should be told of the risk
of SUDEP (Table 1 question (A)). There was a fairly
even split between those who would tell only the pa-
tient (45.2%) and those who would also warn the par-
ents (52.7%), assuming the patient to be over 16 years
old and of normal intelligence (Table 1 question (B)).
After the case history had been presented, most audi-
ence members felt that they would seek legal advice
if invited to attend an inquest (Table 1 question (C)).
Dr Bill Smith (medical legal advisor) strongly advo-
cated seeking such advice from a medical defence so-
ciety. Although a significant proportion of the audi-
ence felt that they would seek advice from their Trust,
it should be remembered that Trusts may have their
own agenda.
Coroners are not permitted to place blame during
an inquest, so the ‘rapping’ in this case would have
originated from the family and the newspaper. Taking
a considerate approach with relatives is particularly
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Table 1:
(A) Whom do you tell about the risk of SUDEP:
All patients 65.4%
New patients 10.3%
Those who do not comply with medication 22.1%
No patients 2.2%
(B) Assuming over 16 and normal intelligence:





(C) If invited to attend an inquest would you seek
legal representation:
Always (cannot be too careful) 31.9%
Never (makes you look guilty) 1.4%
Take advice from hospital Trust 31.2%
Ask my Defence Society 35.5%
important. Focus groups with relatives bereaved by
SUDEP have shown that what families actually want
after the death, is to have an invitation from those in-
volved in the patient’s care to discuss what happened.
Frequently, their aim is to ensure that care is good for
other patients.
Following the discussion, opinion on who should
be warned of SUDEP had changed, with 53.3% of
those present starting that they would now warn more
patients about the condition.
CASE TWO. INCORRECT DIAGNOSIS?
Case history
Professor Richard Dasheiff (an epileptologist from
Oklahoma) described the case history of a 7-year-old
child who developed drop attacks. During the attacks,
the child fell suddenly and floppily to the floor, often
hitting her head. She was pale and inert but not stiff
and did not jerk. She recovered quickly after these at-
tacks with few post-ictal symptoms.
Electroencephalogram (EEG) examination revealed
‘excessive slow activity’ in the right-fronto-temporal
region immediately after a seizure, and a clinical di-
agnosis of atonic seizures was made. Many treatments
were tried but only phenytoin had a beneficial effect on
the condition. However, this was eventually withdrawn
due to unacceptable side effects. At the age of 18, hav-
ing received a poor education through frequently miss-
ing school, she was transferred to adult neurological
care. An EEG and magnetic resonance imaging scan
(MRI) were both normal but no attempt to monitor the
seizures was made as it was felt that they were not oc-
curring frequently enough (once or twice a week). She
failed to gain employment and lived quietly at home
with her ageing parents.
At this stage the audiences opinion was taken on the
points given in Table 2.
Table 2:
(A) On the facts presented what investigation would you
most like to do next?
Ambulatory EEG 24.0%
Video/EEG monitoring 57.5%
Sleep deprived EEG 5.5%
ECG 13.0%
(B) Do you have your own ideas about the diagnosis on the facts
presented?
Emotional pseudoseizures 10.9%
Resistant frontal epilepsy 37.0%
Resistant primary generalized epilepsy 10.9%
Syncope 41.2%
Further developments
At the age of 27 the patient fell and fractured her
shoulder. When admitted to hospital an electrocar-
diogram (ECG) showed a corrected QT interval of
670 milliseconds. She was admitted to a cardiology
unit where a pacemaker was fitted which prevented
further drop attacks. The consultant neurologist, the
GP and the paediatrician received a solicitor’s letter
alleging the diagnosis of the Romano Ward syndrome
(prolonged QT interval) should have been made ear-
lier. The letter stated that not to perform an ECG and
video monitor seizures in a person with apparently re-
sistant epilepsy was negligent. Substantial damages
were claimed for the patient’s poor education and
consequently poor employment prospects. In court a
renowned, but long-retired, neurologist gave his expert
opinion that a routine ECG was not necessary for the
investigation of epilepsy, and the case was settled out
of court.
Discussion
When a patient is not responding to treatment as ex-
pected, ideally they should be moved to a more ad-
vanced level of care. However, circumstances do not
always permit this and the care that the patient in this
case received can be considered as standard. Since
doctors practice to a medical standard, not a legal
one, a misdiagnosis does not equate with negligence.
The Romano Ward syndrome was not widely reported
in the literature until 1999, and even then was not
commonly mentioned in standard epilepsy textbooks.
From a legal perspective, it is important to consider
what constitutes an expert opinion. As discussed ear-
lier, it is preferable to have an expert witness who
has specialist epilepsy knowledge. The evidence base
from which such experts draw their opinions should
also be taken into account.
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The original diagnosis in this case appears to have
been based on ambiguous EEG findings. EEGs are dif-
ficult to interpret in children and might have been mis-
leading if they were recorded immediately after the pa-
tient had struck her head. Had there been more focus
on the simple question ‘Is this epilepsy or not?’, an
ECG would have been performed. Moreover, the per-
ception that this patient’s epilepsy was well controlled
was a confounding factor: had there been recognition
that one or two seizures weekly is still a problem, re-
investigation would have been carried out earlier.
After the initial symptoms the girl was experienc-
ing had been presented, the majority of the audience
(57.5%) felt that video EEG monitoring was the inves-
tigation they would most like to do next (Table 2 ques-
tion (A)). The most likely diagnoses at this stage were
thought to be frontal epilepsy resistant to medication
(37.0%) or syncope (41.2%) (Table 2 question (B)).
Interestingly, the majority of audience members when
asked for a show of hands were of the opinion that
it is mandatory to perform an ECG examination on
a patient suspected of having epilepsy, unlike the ex-
pert neurologist in the case. It should be remembered
that although a single ECG channel is usually recorded
during video EEG monitoring, and can be obtained
during ambulatory EEG monitoring, it may not be of
sufficient quality to measure the PR or QT interval:
proper measurement is obtained from a proper ECG.
EEG monitoring might have revealed that the attacks
were not epileptic, but may well not have revealed the
true cause of them.
CASE THREE. INCORRECT INVESTIGATION?
Case history
Dr Colin Mumford (consultant neurologist) intro-
duced the case history of a 38-year-old man who de-
veloped complex partial seizures in 1994. The pa-
tient suffered loss of awareness, left-sided motor phe-
nomena and subsequent Todds paralysis. A General
Physician investigated his condition by EEG and com-
puted tomography (CT) scan, both of which were nor-
mal. An MRI scan was not performed as there was
a 12 month waiting list for this investigation at the
nearest regional centre (40 miles away) and referral
could only be made to it by a neurologist: there was a
12 month wait for this opinion. The patient’s seizures
were controlled for 2 years with carbamazepine but re-
turned in 1996 and became secondarily generalized.
Re-investigation (using MRI) by another consultant
(the patient had moved) revealed a large right-sided
parietal astrocytoma which was judged to be inoper-
able: despite decompression and radiotherapy, the pa-
tient died.
Further developments
The original physician received a letter from a solicitor
acting on behalf of the patient’s family, alleging negli-
gence in not detecting the tumour earlier when it might
have been operable. The letter also alleged that exam-
ination by CT is known to be inferior to MRI in inves-
tigating epilepsy and that published guidelines compel
the investigation of epilepsy by MRI. The case was
settled out of court by the consultant’s Trust without
admission of liability, having obtained an expert opin-
ion that the case was indefensible. This was despite
the opinion of another expert (a neurosurgeon) stating
that even if the tumour had been detected in 1994, it
probably would not have been operable.
Discussion
It is clear from this case that the Trust had its own
agenda, which was to avoid publicizing the fact that
it was not delivering adequate care to patients. Conse-
quently the matter was settled out of court.
Generally, MRI is thought to be a superior scan-
ning technique compared with CT. However, it is
not an ideal world and availability of MRI is often
restricted. Furthermore, despite the accepted superi-
ority of MRI, it may not always be the most ap-
propriate imaging technique to use at the start of
epilepsy. A controlled trial of the usefulness of CT
vs. MRI at diagnosis would be invaluable. Although
the solicitor in this case alleged that guidelines com-
pel the use of MRI, in reality the wording of the
guidelines is not that extreme. The guidelines of the
Royal College of Physicians in England do suggest
that MRI is appropriate in patients with localization-
related seizures3. However, whilst suggesting that
imaging be carried out in patients with localization
seizures, the Scottish Intercollegiate Guidelines Net-
work (SIGN) (www.show.scot.nhs.uk/sign/) ac-
knowledges that local circumstances may require this
to be a CT scan rather than MRI. GPs are in a diffi-
cult position as the ‘gatekeepers’ of resources. In fact,
given that availability of MRI is a resource problem, it
might be appropriate to sue the Trust involved for not
providing the necessary resources.
Before the outcome of the case was discussed, the
audience was divided on whether they would inves-
tigate all suspected epilepsy cases at onset by MRI
scanning or only use it when there was clear clini-
cal (EEG) evidence of partial onset (Table 3(A), ques-
tion 3). At this stage is was felt the fault lay with the
original physician for not pushing investigations and
with the Trust for not improving facilities (Table 3(B),
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question 3). Although some audience members were
happy with their current scanning policy, discussing
this case left a large number feeling that they would
be more insistent with their Trust over providing im-
proved scanning resources (Table 3(C), question 3).
CASE FOUR. LATROGENIC BRAIN DAMAGE?
Case history
Dr Greg Rogers (GP) reported the case history of
a patient with a troubled background. The boy had
a history of repeated short-term psychiatric care for
overdosing and recurrent wrist slashing and developed
seizures at the age of 14 following a sexual assault
whilst in foster care. On investigation by a paedia-
trician, EEG examination revealed bilateral paroxys-
mal theta activity, although a CT scan was normal and
drug treatment was started. At the age of 15 the patient
was transferred to an adult neurologist, who continued
to prescribe antiepileptic drugs (AEDs): a combina-
tion of sodium valproate and phenytoin provided the
best control. He was reviewed yearly in the neurol-
ogy clinic. Prescribing was carried out by the GP who
measured his serum phenytoin levels every 6 months:
levels were consistently reported as being in the upper
part of the therapeutic range. At the age of 22, the pa-
tient complained of unsteadiness and nausea. He was
re-referred to the neurologist who found his phenytoin
level to be within the normal therapeutic range and
ascribed his ataxic symptoms to ‘attention seeking’.
The patient’s symptoms worsened and he was referred
to the local psychiatric services: by this time he was
wheelchair bound.
Table 3:
(A) When should, in your opinion, epilepsy be investigated
by MRI scanning?
All cases at onset 41.2%
Evidence of partial onset 36.0%
Cases with no response to treatment 19.1%
If CT scan is normal 3.7%
(B) Whom do you think is most liable for not investigating
the patient fully?
The GP, for not insisting on better facilities? 33.6%
His Trust, for not providing them? 25.8%
The Regional Centre, for its obstructive policy? 18.0%
None of them? 22.7%
(C) As a result of this discussion will you:
Review your scanning policy? 26.6%
Remain satisfied with you present policy? 21.8%
Bully your Trust to improve? 42.7%
Consult my Defence Society? 8.9%
Table 4:
(A) At this stage what do you judge to be most likely to be





(B) Is there an interaction between valproate and phenytoin?
No 14.5%
Phenytoin increases the bound fraction 17.1%
of valproate
Both drugs compete for folic acid binding
sites in the cerebellum 26.3%
*Valproate increases the unbound fraction 42.1%
of phenytoin
*The correct answer
(C) Be honest—did you know of this interaction?
Yes 16.3%
Vaguely 46.3%
Not at all 36.6%
Are you sure there is one—it’s not in the BNF 0.8%
(D) The remedy is:
Measure free phenytoin levels 12.3%
Increase the dose of valproate 2.6%
Add folic acid 2.6%
Avoid this drug combination wherever possible 82.5%
At this point the audience were asked to indicate
what they felt the diagnosis to be: most chose a psy-
chological cause (Table 4 question (A)) They were
also asked if they knew of any interaction between val-
proate and phenytoin (Table 4 question (B)), but less
than 50% knew the right answer.
Further developments
The psychiatrist, suspecting that the patient’s severe
ataxia was organic, referred him to a second neurol-
ogist who agreed. An MRI scan showed severe cere-
bellar atrophy consistent with phenytoin intoxication.
The GP received a solicitor’s letter alleging negligence
on the grounds that he prescribed the phenytoin and
that he ‘should have known of the dangers of prescrib-
ing phenytoin in patients taking valproate when the
unbound fraction of phenytoin increases and that, in
those circumstances, intoxication and cerebellar dam-
age can occur even when serum levels of phenytoin
(which measure both the bound and unbound frac-
tions of phenytoin) appear to be within the therapeutic
range’.
Despite an expert witness for the defence stating that
he would not expect a GP to know of the interaction
between phenytoin and valproate (since it is not men-
tioned in the British National Formulary or the stan-
dard British Textbook4), a second expert witness (a
GP) disagreed. The case was settled against the GP
for a large sum of money: the original neurology con-
sultant was not involved in the dispute, although he ad-
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mitted that he was not aware of the interaction himself.
The patient, who clearly had a conversion disorder and
not epilepsy, was taken off all AEDs but made only a
partial recovery from his ataxia.
Discussion
A serum phenytoin level is a measure of the total
phenytoin of which around 10% is free, unbound and
active. Valproate co-therapy increases this unbound
fraction so that although serum levels may appear
normal, the proportion of active phenytoin may have
reached damaging levels. However, this interaction is
not widely reported in the British literature. If consul-
tant neurologists should certainly be aware of it, what
about GPs? Again, we come back to the question of
what is a responsible expert opinion. Although the GP
treating the patient was not aware of the interaction,
he was correct in referring the patient to a neurologist
when his condition changed. He also maintained good
links between primary and secondary care. It should
be remembered that GPs are dealing with an ever in-
creasing number of drugs and that even with the aid
of a computerized prescribing system, it is extremely
difficult to stay informed of all possible interactions:
the valproate/phenytoin is not to be found on British
GPs computerized prescribing information.
Less than 50% of audience members identified cor-
rectly that valproate increases the unbound fraction
of phenytoin (Table 4 question (B)). Almost half ad-
mitted when challenged (Table 4 question (C)) that
they had previously been only vaguely aware of this
interaction. The majority of those present (82.5%)
stated that they would now avoid this drug combina-
tion wherever possible when asked what they would
do in the future now they were informed of the in-
teraction (Table 4 question (D)): this may be a slight
over-reaction.
I was pleased to see that my little textbook5 does
warn against this little known but important interac-
tion: since it is difficult to routinely measure unbound
fractions of AEDs (a similar difficulty occurs in preg-
nancy) perhaps it is better to avoid the combination,
although the interaction does not occur in every pa-
tient taking a mixture of the two drugs6.
CASE FIVE. UNEXPECTED PREGNANCY?
Case history
Annette Russell (Nursing Development Manager) re-
lated the case of a 15-year-old girl with complex par-
tial seizures. She had been under the care of the same
paediatrician for 5 years and her seizures were well
controlled with carbamazepine. The paediatrician had
not enquired if she was sexually active when he ar-
ranged her transfer to an adult service, but on her
last visit (to his clinic nurse) it was discovered she
had been sexually active for some time. The nurse ad-
vised her to go to a family planning clinic but did not
warn her that there was an interaction between carba-
mazepine and oral contraceptives as she assumed the
clinic would do this. The family planning clinic pre-
scribed an ordinary dose of the pill. When the patient
arrived at the adult neurology clinic, examination re-
vealed that she was 4 months pregnant: she decided to
keep the child and was consequently forced to give up
college.
Further developments
The paediatrician received a solicitor’s letter alleging
negligence in not informing the girl of the risk of preg-
nancy if the contraceptive pill is taken in combina-
tion with an enzyme-inducing AED. The letter also
stated that it was a well know principle that doctors
are responsible for the ‘acts and omissions of their
servants’, in this case, the nurse. The defence of the
paediatrician and his nurse was successful but the case
is still being pursued against the doctor at the family
planning clinic. Examination of the family planning
clinic’s records suggests that the girl did not inform
the doctor that she was taking carbamazepine.
Discussion
From a legal standpoint it is the Trust who is responsi-
ble, not the individuals concerned. However, it is un-
fortunate that the nurse missed a valuable opportunity
to warn the girl of the risk of interaction between car-
bamazepine and enzyme-inducing AEDs. It may also
be considered as her responsibility to do so, given that
she discovered the girl was sexually active. It was dan-
gerous to assume that someone else would carry out
this task.
Paediatricians may find cases such as this one par-
ticularly difficult to manage. Treating patients from
a very early age may increase the difficulty of defin-
ing the point at which adult (sexual) issues should
be discussed, particularly if the parents are present.
The situation is further complicated by the fact that
patients seeking contraception may prefer to visit a
family planning clinic because they want to avoid their
regular physician. Although this kind of independent
advice is an important option for patients to have, it




(A) Which of these drugs is enzyme inducing as far as a




None of them 30.0%
The correct answer is topiramate
(B) Which of these drugs is not enzyme inducing as far as a




All of them 17.3%
The correct answer is ethosuximide
The audience showed poor awareness of which
drugs are enzyme inducing with respect to the con-
traceptive pill (Table 5 questions (A) & (B)), but were
better than a recent survey of American neurologists7.
The majority (73.2%) agreed that all female patients of
child-bearing age should be asked if they are (or might
become) sexually active before being prescribed an
AED. The majority of the audience (78.9%) also felt
that doctors should routinely ask women with epilepsy
about their contraceptive practice.
CASE SIX. INCORRECT RISK ASSESSMENT?
Case history
Dr Bill Smith (medical legal advisor) presented the
case history of a 20-year-old woman with juvenile
myoclonic epilepsy seeking pre-conception advice,
which, in her clinic, was delegated by the neurolo-
gist to a nurse. Her condition had been well controlled
since the age of 14 with valproate (400 mg daily). The
specialist epilepsy nurse informed the patient, when
she asked for pre-conception advice, that the risk of
foetal damage with this dose of valproate was low and
advised that she should continue taking it. The nurse
also advised that it was not clinic policy to prescribe
a high dose of folic acid as there was no clear evi-
dence to suggest that it protected against AED-induced
teratogenesis and advised that she should continue to
take the normal dose for all pre-conceptual women of
400 mcg daily.
At this stage a majority of the audience correctly
identified that a family history was an important part
of the woman’s investigations (Table 6 question (A)).
Further developments
The nurse unfortunately did not ask whether there was
a history of spina bifida in the patient’s family. In fact,
there was a history of the disease in the blood lines
of both the patient and her partner and it was later
discovered that the patient herself suffered from spina
bifida occulta. The patient later conceived: the foetus
was found to have a severe spina bifida and the preg-
nancy was subsequently terminated, with much emo-
tional trauma to the woman and her partner.
The consultant received a solicitor’s letter alleging
negligence in not fully warning against the risks of
spina bifida and stating that guidelines recommend a
higher dose of folic acid. He was also held account-
able for the ‘acts and omissions’ of his nurse. The case
was considered indefensible. Although there is no ev-
idence to support the benefit of high dose folic acid
against AED-induced malformation, there is substan-
tial evidence that it protects against the genetically de-
termined risk of spina bifida. The claim was settled
out of court by the employing Trust, but the consultant
was held partly to blame for not ensuring that the per-
son to whom he delegated the task of counselling was
competent to do so.
Table 6:
(A) Before assigning risk is there any other investigation
you would like to carry out?
Blood level of valproate 17.0%
Folic acid level 13.6%
X-ray of lumbar spine 4.5%
Family history 64.8%
(B) In the human is there any published evidence to suggest
that folic acid given to women taking valproate:
Protects against spina bifida 56.4%
Does not protect against spina bifida 1.7%
Increases the risk of spina bifida 3.4%
∗No evidence either way 38.5%
∗The correct answer
(C) In the rat is there any published evidence to suggest that
folic acid given to females also taking valproate:
Protects against spina bifida 71.2%
Does not protect against spina bifida 7.7%
!Increases the risk of spina bifida 2.9%
*No evidence either way 18.3%
!This is true for the mouse exposed to phenytoin and
folic acid pre-conceptually (Schardein et al.8)
∗The correct answer (Craig et al. 19999)
(D) In the light of the discussion would you give
pre-conception advice to women with epilepsy:
Yourself 28.9%
With a colleague 22.8%
Would tell GP to do it 4.4%
∗Would refer to specialist clinic 43.9%
∗Very few such clinics exist
Epilepsy—doctor’s dilemma, lawyer’s delight? 83
Discussion
The General Medical Council has made it clear that
duty can only be delegated to people who are capable
of providing the standard of care that would be ex-
pected of (and by) the doctor. In this case, the nurse
failed to take a full history having had that responsi-
bility delegated to her. The British National Formu-
lary (BNF) states the position on folic acid in detail.
In cases where there is a family history of spina bi-
fida, it advises a folic acid supplement of 5 mg be-
fore and during pregnancy, particularly during the first
trimester.
Most of the audience agreed that they would have
taken a family history in this case. The majority
(56.4%)—(Table 6 question (B))—thought they were
aware of evidence supporting the protective effect
against spina bifida of folic acid in pregnant women
taking valproate (although there is none). However,
they were mainly unaware (Table 6 question (C)) that
there is now evidence that a spina bifida pregnancy has
occurred in a woman taking valproate even though she
had been taking the higher dose of folic acid9. In light
of the discussion, the majority of those present would
either give pre-conception advice themselves or refer
patients for specialist pre-conception advice (Table 6
question (D)). However, the problem in this case was
mainly one of communication. If pre-conception ad-
vice is given by doctor and nurse together, a greater
range of issues can be covered and any omissions iden-
tified (Fox, 2000)10. Use of a pre-conception coun-
selling protocol is a valuable tool in this setting11.
CONCLUSIONS
The content of this symposium was particularly topi-
cal. Following a recent Court of Appeal test case, and a
consultation exercise by the Lord Chancellor, the Na-
tional Health Service bill for clinical negligence looks
set to rise again (Dyer, 2000)12. The Appeal Court’s
ruling states that damages compensating for the effects
of injuries on bodily functions and enjoyment of life
should increase by one third. This was actually a relief
to the NHS: the court rejected a recommendation from
the Law Commission for an increase of 50% to 100%.
The value of expert testimony and the relevance of
clinical guidelines were among the important issues
raised by our discussions. In several of the cases, the
knowledge and motives of the expert witness were
questionable at best. Stringent investigation of the
background and level of knowledge of such a wit-
ness is called for: epilepsy specialists should volun-
teer their services as expert witnesses more frequently.
Although guidelines can be introduced to a court by
an expert witness as evidence of accepted standards of
care, they cannot be substituted for expert testimony.
However well-linked to evidence, clinical guidelines
need to be interpreted and applied sensibly. There is
no doubt that the widespread adoption of relevant ev-
idence based guidelines cannot be seen as prima facie
evidence of negligence.
It is important to bear in mind that the courts are
only part of the system for resolving disputes. They are
concerned with identifying where practices have fallen
short, not necessarily in identifying good practice. Of
course there are areas where the clinical management
of epilepsy could be improved. The management of
women with epilepsy has been the subject of recent
attention and in response to this, effective guidelines
have been produced (Crawford et al., 1999)13. An-
other area of concern is delegation of duty, particu-
larly as the numbers (and responsibilities) of special-
ist epilepsy nurses increase. The medico-legal issues
surrounding epilepsy care are complex but more open
debate will raise awareness of the main issues.
The meeting also demonstrated that knowledge in
the epilepsy field is changing rapidly and the different
practitioners who make up the ‘epilepsy field force’ do
not share the same knowledge base and are sometimes
surprisingly ignorant (for example, as to which AEDs
are—or are not—enzyme inducing). We can do very
little about the patchy nature of epilepsy services in
the UK as individuals, but we can improve our knowl-
edge and make sure that any advice we give (whatever
our professional background) is informed up to date
advice.
For this reason the Editor and Editorial Board of
Seizure have decided, as a priority, to institute a Con-
tinuing Medical Education Section to enable our read-
ers, whatever their discipline, to develop their knowl-
edge and keep abreast of new developments in all
fields of epilepsy. I am grateful to Professor Stephen
Brown and his team for taking on this task and wish
them all success.
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